@article{discovery10151855, note = {{\copyright} 2022 The Authors. Alzheimer's \& Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.}, publisher = {WILEY}, month = {June}, year = {2022}, title = {Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study}, journal = {Alzheimer's \& Dementia}, keywords = {Science \& Technology, Life Sciences \& Biomedicine, Clinical Neurology, Neurosciences \& Neurology, amyloid, Alzheimer's, dementia, memory clinic population, mild cognitive impairment, PET, subjective cognitive decline, ALZHEIMERS ASSOCIATION WORKGROUPS, NATIONAL INSTITUTE, WORK-UP, DEMENTIA, DISEASE, RECOMMENDATIONS, GUIDELINES}, author = {Altomare, Daniele and Collij, Lyduine and Caprioglio, Camilla and Scheltens, Philip and van Berckel, Bart NM and Alves, Isadora Lopes and Berkhof, Johannes and de Gier, Yvonne and Garibotto, Valentina and Moro, Christian and Poitrine, Lea and Delrieu, Julien and Payoux, Pierre and Saint-Aubert, Laure and Luis Molinuevo, Jose and Grau-Rivera, Oriol and Gispert, Juan-Domingo and Minguillon, Carolina and Fauria, Karine and Felez Sanchez, Marta and Radoi, Andreea and Drzezga, Alexander and Jessen, Frank and Escher, Claus and Zeyen, Philip and Nordberg, Agneta and Savitcheva, Irina and Jelic, Vesna and Walker, Zuzana and Lee, Ho-Yun and Lee, Lean and Demonet, Jean-Francois and Wuthrich, Sonia Plaza and Gismondi, Rossella and Farrar, Gill and Barkhof, Frederik and Stephens, Andrew W and Frisoni, Giovanni B}, url = {https://doi.org/10.1002/alz.12696}, abstract = {INTRODUCTION: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort. METHODS: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. RESULTS: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35\% of participants to ARM1, 32\% to ARM2, and 33\% to ARM3; cognitive stages were distributed equally across the arms. DISCUSSION: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.} }